Diethyl phthalate with methyl salicylate
Brand names: various rubefacients
Diethyl phthalate with methyl salicylate is a topical insecticidal preparation traditionally used in the treatment of scabies and certain lice infestations.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Diethyl phthalate provides the parasiticidal/repellent action against ectoparasites, while methyl salicylate is included as a counter-irritant with mild analgesic and antipruritic effect.
Prescribing in practice
- For external use only; avoid contact with the eyes, mucous membranes and broken or inflamed skin, and avoid extensive application in young children.
- It is an older preparation that has largely been superseded by more selective topical insecticides for routine scabies and lice treatment.
- Treat close contacts where appropriate and advise on environmental and laundry measures to prevent reinfestation.
Monitoring
Monitoring is clinical, based on eradication of infestation, relief of itch and any local skin irritation.
Counselling the patient
- Apply only to intact skin and keep it away from the eyes and mouth.
- Itching may persist for a while after successful treatment and does not always mean it has failed.
- Stop and seek advice if marked skin irritation occurs.
Evidence & guidelines
This combination is a traditional topical antiparasitic; current prescribing references favour more selective insecticides as first-line for scabies and lice.
Reference: NICE NG100; NICE NG59; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD